Vertex Stock Is Down. Its Painkiller Could Spark Big Gains.

Disappointment about the construction of a drug trial has caused Vertex stock to fall. Better times may be ahead.

Related Keywords

San Diego ,California ,United States ,Salveen Richter ,Danielle Brill ,Goldman Richter ,Jacob Sonenshine ,Raymond James ,Brian Abrahams ,Evan Seigerman ,Polaris Market Research ,Courtesy Vertex Pharmaceuticals Incorporated ,Goldman Sachs ,Vertex Pharmaceuticals ,Polaris Market ,Cystic Fibrosis ,Article Normal ,Pharmaceuticals ,Analgesics ,Scientific Research Services ,Healthcare Life Sciences ,Business Consumer Services ,Specialized Drugs Medications ,Medical Research Services ,Drug Discovery Development ,Healthcare Support Services ,Diagnostic Medical Research Services ,Financial Performance ,Corporate Industrial News ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Synd ,The Trader ,Biotech And Pharma ,Vrtx ,Vertex ,S Amp Ampp 500 Index ,Spx ,Corporate ,Industrial News ,Healthcare ,Life Sciences ,Business ,Consumer Services ,Specialized Drugs ,Medications ,Drug Discovery ,Development ,Diagnostic ,